CD4 and neoplasm: The therapeutic applications of a neoantigen are also directly impacted by the potential of the neoantigen to bind to MHC class II and elicit a CD4+ T cell response, as CD4+ T cells have been demonstrated to play a critical role in initiating and maintaining a successful immune-mediated tumor destruction (6, 117).